MedTrace Logo

Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients

NCT00128908 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2009-09-15

No results posted yet for this study

Summary

This is an open label, crossover pilot study to explore the safety and efficacy of a rapid cycling regimen of antiretroviral combination therapy in HIV-1 infected patients with virus harboring genotypic resistance to at least three classes of antiretroviral therapy.

Conditions

  • HIV Infections

Interventions

DRUG

Standard Continuous Highly Active Antiretroviral Therapy (HAART)

DRUG

Rapidly Cycled HAART

Sponsors & Collaborators

  • Dutch AIDS Fund

    collaborator UNKNOWN

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Joep MA Lange, MD PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • Ferdinand Wit, MD PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00128908 on ClinicalTrials.gov